You are here

Perspectives in Lung Cancer 2017

HOW I OPTIMIZE TREATMENT FOR MY NSCLC PATIENTS WITH ADVANCED AND AGGRESSIVE DISEASE

Welcome video Dr. Novello - Perspectives in Lung Cancer 2017

Program objectives:

  • To state that there are limited treatment options for advanced squamous NSCLC,  especially those with aggressive disease, and understand the reasons underlying this and  the need for more effective therapies despite recent advances in treatment.
  • To describe the different current and emerging treatment modalities (targeted, angiogenesis,  immuno-oncology) for both squamous and non-squamous advanced NSCLC, and summarize their efficacy and safety in recent clinical trials.
  • To develop a care plan based on personalized treatment strategies including effective sequencing so as to optimize the multidisciplinary management in daily practice.
  • To recognize the subset of patients with aggressive disease and be able to develop management strategies for these patients.

 

PROGRAMME

11:40-11:45 Welcome and introduction - 5 minutes
Silvia Novello

  • Introduction of the faculty, learning objectives, interactivity, and housekeeping notes
  • Baseline questions to audience using interactive polling (measurement of knowledge level)

11:45-12:05 How I select the right treatment for the right patient: histological and molecular profiling challenges
Fernando López-Ríos

  • Brief overview of epidemiological data
  • From precise pathological diagnosis to personalised therapy: role of histological and molecular profiling
    - What should be determined and how: cytology and liquid biopsies
  • Case-based examples to illustrate the impact of diagnostics on treatment options

12:05-12:35 How I optimize treatment for my patients with advanced non-squamous NSCLC: present options and future perspectives
Joachim Aerts

  • Presentation of efficacy and safety data of 1st-line treatment options for patients with non-squamous NSCLC based on efficacy and safety data of currently available therapies
    - Brief overview of current guidelines
    - Brief overview of frontline data from clinical trials
  • Presentation of 1-2 clinical cases to illustrate the remaining challenges in 2nd-line treatment options for patients with non-squamous NSCLC (example: patient with aggressive ADC)
    - Brief overview of current guidelines
    - Brief overview of 2nd line data from clinical trials

12:35-13:05 How I optimize treatment for my patients with advanced squamous NSCLC: present options and future perspectives
Luis Paz-Ares

  • Presentation of efficacy and safety data for currently available frontline therapies for patients with squamous NSCLC
    - Brief overview of current guidelines
    - Brief overview of frontline data from clinical trials
  • Presentation of 1-2 clinical cases (e.g. of an elderly patients with co-morbidities) to illustrate efficacy and safety of novel 2nd-line therapies for patients with squamous NSCLC
    - Brief overview of current guidelines
    - Brief overview of frontline data from clinical trials

13:05-13:10 Summary and key learning points 
Silvia Novello

  • Brief summary of symposium
  • Post-test questions to audience using interactive polling to test how well the learning objectives were addressed

TAKE PART IN OUR PREMEETING SURVEY   DOWNLOAD INVITE

Mar 2017
3

Address details

Hotel Meliã Avenida América
Calle de Juan Ignacio Luca de Tena, 36
28027 Madrid Madrid
Spain

Add to calendar

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Perspectives in Lung Cancer 2017 About the Speakers

Silvia Novello, MD, PhD

Silvia Novello, MD, PhD

Oncology Department, University of Turin, and Thoracic Oncology Unit, San Luigi Hospital Orbassano,Italy

Silvia Novello is Full Professor of Oncology at the University of Turin and Director of the ThoracicOncology Unit at the San Luigi Hospital in Orbassano, Italy. Professor Novello received her medicaldegree from the University of Turin in 1995, and completed a postgraduate course in respiratorymedicine “summa cum laude” at the same university in 1999, then achieved a PhD in human oncologyand conducted postgraduate research in medical oncology.

Professor Novello’s main areas of research are basic and applied clinical research into thoracicmalignancies, and gender differences in lung cancer. She has been involved in trials and studies indifferent clinical stages of lung cancer and pleural mesothelioma, including: supportive care; thetreatment of lung cancer in elderly patients; the role of cytokines in thoracic malignancies; the role ofoncogenes, anti-oncogenes, and growth factors and their receptors in lung cancer; women and lungcancer; pharmacogenomics and lung cancer; and applied clinical research into aspects of interstitial lungdisease.

Professor Novello is a member of American Society of Clinical Oncology (ASCO), and has been a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC) since 2011. She is also a member of the National Lung Cancer Partnership (NLCP) Scientific Committee; a member of the IASLC Young Investigators Awards Scientific Committee; a member of the Board of Directors of the Italian Association of Medical Oncology (AIOM); and current President of Women Against Lung Cancer in Europe (WALCE), a non-profit European association founded in Turin, in 2006. She has authored or co-authored over 100 publications in peer-reviewed journals, and book chapters published in scientific volumes.

Fernando López-Ríos, MD, PhD

Fernando López-Ríos, MD, PhD

Targeted Therapies Laboratory, Hospital Universitario HM Sanchinarro, and Universidad CEU San Pablo,Madrid, Spain

Fernando López-Ríos is Director of the Targeted Therapies Laboratory at the Hospital Universitario HMSanchinarro and Professor of Pathology and Molecular Pathology at Universidad CEU San Pablo inMadrid, Spain. He received his medical and PhD degrees from the Faculty of Medicine at the UniversidadAutónoma de Madrid and the Universidad Complutense, respectively, and completed his residency inpathology at the Hospital Universitario 12 de Octubre, all in Madrid. Dr López-Ríos has also been avisiting researcher at the Memorial Sloan Kettering Cancer Center in New York, NY, USA.
His main clinical and research expertise is in cancer biomarker testing, with a special emphasis on lungcancer.

Joachim G. Aerts, MD, PhD

Joachim G. Aerts, MD, PhD

Thoracic Oncology Department, Erasmus MC, Rotterdam, Netherlands

Joachim Aerts is currently Chair of the Thoracic Oncology Department at the Erasmus University MedicalCenter (Erasmus MC) in Rotterdam, the Netherlands. He obtained his medical degree and completed hisPhD studies both at the Erasmus University in 1996.

His research interests include preventive medicine, pathophysiology, and different treatment options.Professor Aerts performs basic, translational, and clinical studies mainly in lung cancer andmesothelioma, with a special focus on onco-immunology. His group has developed a new concept ofimmunotherapy in mesothelioma for which he was granted a Horizon 2020 subsidy from the EuropeanUnion. He is Principal Investigator for several national and international studies.

Professor Aerts is a member of several major scientific societies, including the International Associationfor the Study of Lung Cancer (IASLC), the American Association for Cancer Research (AACR), theAmerican Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO).He has authored or co-authored over 120 publications in peer-reviewed journals and books.

Luis Paz-Ares, MD, PhD

Luis Paz-Ares, MD, PhD

Medical Oncology Department, Hospital Universitario 12 de Octubre, and Universidad Complutense,Madrid, Spain

Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 deOctubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at theCNIO (Spanish National Cancer Research Centre), all in Madrid, Spain. He graduated with a degree inmedicine from the Universidad Autónoma de Madrid in 1986, and earned his PhD degree there in 1993.Professor Paz-Ares was a postdoctoral European Society for Medical Oncology (ESMO) research fellow inmedical oncology at the Beatson Oncology Centre, University of Glasgow, Scotland (1993–1995), andearned Master’s degrees in clinical pharmacology at the University of Glasgow (1995) and in clinical unitmanagement at the UNED–Fundación Universidad-Empresa, Madrid (2002–2003).

Prior to his current position, Professor Paz-Ares was Chair of the Medical Oncology Department at theUniversity Hospital Virgen del Rocío in Seville, Spain (2007–2014), Head of the Pharmacology Unit andresponsible for early clinical studies of thoracic and genito-urinary tumours at the Hospital Universitario12 de Octubre (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Program atthe Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).

Professor Paz-Ares’ research focuses on lung cancer and the development of new therapeutic strategies,in both the lab and the clinic. He has published more than 240 papers in peer-reviewed journals,including New England Journal of Medicine, The Lancet, The Lancet Oncology, and Journal of ClinicalOncology, and written many book chapters. Professor Paz-Ares is an active member of various scientificsocieties, including the American Society of Clinical Oncology (ASCO), the European Society for MedicalOncology (ESMO), and the International Association for the Study of Lung Cancer (IASLC), andcollaborative groups, such as the European Organisation for Research and Treatment of Cancer (EORTC),the Spanish Lung Cancer Group (GECP), and the International Germ Cell Cancer Collaborative Group.